Berobenatide clinical trials
Also written PF-08653944 and MET097.
How each study uses berobenatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the berobenatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2026 (17)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 0
Pfizer (22) · Metsera, a wholly owned subsidiary of Pfizer (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test berobenatide, phase 3 first.
- Sep 2027Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityPhase 3 · Pfizer
- Oct 2027A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)Phase 3 · Pfizer
- Jan 2027A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityPhase 1 · Pfizer
- Feb 2027A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or ObesityPhase 1 · Pfizer
- Apr 2027A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or ObesityPhase 1 · Pfizer
- Jul 2027A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver FunctionPhase 1 · Pfizer
Studies
Open first, then newest update. How each study uses berobenatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or OverweightNot yet recruitingPhase 3PfizerNCT07932925Written as Berobenatide
- A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)RecruitingPhase 3PfizerNCT07794774Written as Berobenatide
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or ObesityRecruitingPhase 3PfizerNCT07874633Written as Berobenatide
- A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or ObesityRecruitingPhase 1PfizerNCT07876531Written as Berobenatide
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)RecruitingPhase 3PfizerNCT07881757Written as Berobenatide
- A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07595549Written as PF-08653944
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityRecruitingPhase 3PfizerNCT07792954Written as Berobenatide
- A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)RecruitingPhase 3PfizerNCT07794761Written as Berobenatide
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)RecruitingPhase 3PfizerNCT07823608Written as Berobenatide
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07845500Written as Berobenatide
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)RecruitingPhase 3PfizerNCT07919678Written as Berobenatide
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)RecruitingPhase 3PfizerNCT07915609Written as Berobenatide
- A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver FunctionRecruitingPhase 1PfizerNCT07519135Written as PF-08653944
- A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or ObesityActive, not recruitingPhase 1PfizerNCT07845513Written as PF-08653944
- A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightCompletedPhase 2PfizerNCT06973720Written as MET097
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesCompletedPhase 1/2PfizerNCT06924320Written as MET097
- A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)Active, not recruitingPhase 3PfizerNCT07400653Written as PF-08653944
- Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityActive, not recruitingPhase 3PfizerNCT07311850Written as MET097
- A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or OverweightCompletedPhase 2PfizerNCT06712836Written as MET097
- A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityCompletedPhase 1PfizerNCT07400679Written as PF-08653944
See all 23 studies that test berobenatide →
Given beside what is tested · 1 — berobenatide is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting4
- A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)Nov 6, 2026NCT07794774
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or ObesityNov 6, 2026NCT07874633
- A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or ObesityNov 6, 2026NCT07876531
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)Nov 6, 2026NCT07881757
Newly registered4
- The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or OverweightNov 12, 2026NCT07932925
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)Nov 5, 2026NCT07919678
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)Nov 4, 2026NCT07915609
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)Oct 19, 2026NCT07881757
Codes
What other systems call berobenatide · ClinicalTrials.gg INT018146
- UNII (FDA) UN3RWY4TEGBEROBENATIDEOne source FDA
- NCI Thesaurus C224718BerobenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UN3RWY4TEG | BEROBENATIDE | One source FDA |
| NCI Thesaurus | C224718 | Berobenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.